Talking About Tumors with Ryann and Ryan - A medical oncology podcast

04_07 Localized Renal Cell Carcinoma

July 06, 2024 Talking About Tumors Season 4 Episode 7
04_07 Localized Renal Cell Carcinoma
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
More Info
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
04_07 Localized Renal Cell Carcinoma
Jul 06, 2024 Season 4 Episode 7
Talking About Tumors

1. Risk Factors and Presentation
2. Staging and Paraneoplastic syndromes
3. Localized Therapy Options and Considerations
4. Evidence and Limitations for Adjuvant Systemic Therapy

 

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. 

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

 


1.           Tannock IF et al. Evaluating Trials of Adjuvant Therapy: Is There Benefit for People with Resected Renal Cancer? Journal of Clinical Oncology. 2023;41(15):2713-2717. doi:10.1200/JCO.23.00280/ASSET/IMAGES/LARGE/JCO.23.00280F2.JPEG

2.           Ravaud A et al. NEJM. 2016;375(23):2246-2254. doi:10.1056/NEJMOA1611406/

3.           Pal SK et al. Lancet. 2022;400(10358):1103-1116. doi:10.1016/S0140-6736(22)01658-0

4.           Motzer RJ et al. Lancet. 2023;401(10379):821-832. doi:10.1016/S0140-6736(22)02574-0

5.           Correa AF et al. Eur Urol. 2021;80(1):20-31. doi:10.1016/J.EURURO.2021.02.025

6.           Choueiri TK et al. NEJM. 2024;390(15):1359-1371. doi:10.1056/NEJMOA2312695/

7.           Choueiri TK et al. NEJM. 2021;385(8):683-694. doi:10.1056/NEJMOA2106391/

 

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

 

Show Notes

1. Risk Factors and Presentation
2. Staging and Paraneoplastic syndromes
3. Localized Therapy Options and Considerations
4. Evidence and Limitations for Adjuvant Systemic Therapy

 

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice. 

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

 


1.           Tannock IF et al. Evaluating Trials of Adjuvant Therapy: Is There Benefit for People with Resected Renal Cancer? Journal of Clinical Oncology. 2023;41(15):2713-2717. doi:10.1200/JCO.23.00280/ASSET/IMAGES/LARGE/JCO.23.00280F2.JPEG

2.           Ravaud A et al. NEJM. 2016;375(23):2246-2254. doi:10.1056/NEJMOA1611406/

3.           Pal SK et al. Lancet. 2022;400(10358):1103-1116. doi:10.1016/S0140-6736(22)01658-0

4.           Motzer RJ et al. Lancet. 2023;401(10379):821-832. doi:10.1016/S0140-6736(22)02574-0

5.           Correa AF et al. Eur Urol. 2021;80(1):20-31. doi:10.1016/J.EURURO.2021.02.025

6.           Choueiri TK et al. NEJM. 2024;390(15):1359-1371. doi:10.1056/NEJMOA2312695/

7.           Choueiri TK et al. NEJM. 2021;385(8):683-694. doi:10.1056/NEJMOA2106391/

 

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic. 

Tags

Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology